SavedAdd your journal

Journals / Romatizma Dergisi / 2008 / Cilt: 23 - Sayı: 2

Evaluation of effectiveness of leflunomide in the treatment of rheumatoid arthritis

Romatoid artrit tedavisinde leflunomid etkinliğinin değerlendirilmesi

Filiz ESER
Hatice BODUR
Lale Akbulut AKTEKİN
Ümit SEÇKİN
Pages
52–55
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These results suggest that LEF is an effective and reliable DMARD for the treatment of RA patients. (Rheumatism 2008; 23: 52-5)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to evaluate effects and side effects of LEF in Rheumatoid Arthritis (RA) patients.
📊
Key Findings & Data:Patient and Methods: 51 RA patients taking LEF for mono-or combination therapy were investigated retrospectively.
💡
Conclusion & Impact:Conclusion: These results suggest that LEF is an effective and reliable DMARD for the treatment of RA patients. (Rheumatism 2008; 23: 52-5)
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Artrit · romatoid · İlaç tedavisi

Abstract

Objective: The aim of this study was to evaluate effects and side effects of LEF in Rheumatoid Arthritis (RA) patients. Patient and Methods: 51 RA patients taking LEF for mono-or combination therapy were investigated retrospectively. Dosage, period of use and other medical therapies were recorded. Erythrocyte sedimentation rates (ESR), C-reactive protein (CRP) levels, number of tender joints and swollen joints were recorded at the beginning, at 6th and 12th months. If LEF stopped, the reasons were investigated. Disease activity scores were calculated with DAS 28 having 3 variables for patients. Results: Thirty one (61%) of RA patients were given monotherapy and 20 (39%) combination therapy. The median DAS 28 values were 4,41±1,3 for the beginning, 3,35±1,1 for 6th month and 3,47±0,9 for 12th month. The improvement of DAS 28 values between the start the 6th and 12th months was statisticaly significant (p= 0,001, p=0,001, respectively). Side effects tcausing medication to be stopped, was seen in 6 patients (11,7%). Elevation of transaminases was seen in 5 patients. These 5 patients were taking combination therapy. Conclusion: These results suggest that LEF is an effective and reliable DMARD for the treatment of RA patients. (Rheumatism 2008; 23: 52-5)

Özet

Amaç: Çalışmamızda Leflunomid'in (LEF) Romatoid Artrit (RA) hastalarında etkinlik ve yan etkilerini değerlendirdik. Hastalar ve Yöntem: LEF mono veya kombine tedavisi alan 51 RA'lı retrospektif olarak incelendi. LEF dozu, kullanma süreleri ve diğer ilaç tedavileri belirlendi. Başlangıç, 6. ve 12. aylardaki eritrosit sedimentasyon hızları (ESH), C-reaktif protein (CRP) değerleri, hassas eklem (HE) ve şis eklem (ŞE) sayıları tespit edildi. LEF kesildi ise, nedenleri araştırıldı. Hastalık aktivite skorları 3 değişkenli DAS 28 ile hesaplandı. Bulgular: RA'lı olguların 31'i (%61) monoterapi, 20'si (%39) kombine terapi kullanmakta idi. DAS 28 değerlerinin ortalamaları başlangıç 4,41±1,3, 6. ay 3,35±1,1 ve 12 ay. 3,47±0,9 idi. DAS 28 değerlerinde başlangıç ile 6. ve başlangıç ile 12. aylar arasında düzelme anlamlı bulundu (sırası ile p< 0,001, p<0,001). Toplam 6 olguda (%11,7) ilaç kesmeyi gerektiren yan etki izlendi. Sonuç: Bu veriler LEF'in RA hastalarında güvenilir ve etkin bir hastalık modifiye edici antiromatizmal ilaç (DMARD) olarak değerlendirilebileceğini göstermektedir. (Romatizma 2008; 23: 52-5)

🔖

Cite This Article

ESER, F., BODUR, H., AKTEKİN, L. A., SEÇKİN, Ü. (2008). Evaluation of effectiveness of leflunomide in the treatment of rheumatoid arthritis. Romatizma Dergisi, Cilt: 23 - Sayı: 2, 52–55. https://ajindex.com/articles/305903

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bodur H. Romatoid Artrit tedavisinde metotraksat ve leflunomid. Romatizma 2006; 21: 60-6
  2. Van Roon EA, Jansen TH A, Mourad l, Houtman pm, Bruyn GAW, Griep EN, et al. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol 2003; 57: 790-7
  3. Pinto P, Dougados M. Leflunomide in clinical practice. Acta Reumatol Port. 2006; 31: 215-24
  4. Edward D, Haris, JR. Clinical features of Rheumatoid Artritis. In: Harris ED, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB (eds) Kelley’s Textbook of Rheumatology. Philadelphia, Elsever Saunders, 2005; 1043-78
  5. Li EK, Tam L-S, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Therapeutics 2004; 26: 447-59
  6. Bettembourg-Brault I, Gossec L, Pham T, Gottenberg JE, Damiano J, Dougados M. Leflunomide in rheumatoid arthritis in daily pratice: Treatment discontinuation rates in comparison with other DMARDs. Clin Exp Rheumatol 2006; 24: 168-171
  7. Nguyen M, Kabir M, Ravaud P. Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use: open-label, prospective study. Clin Drug Investig. 2004; 24: 103-12
  8. Koyuncu H, Bozok N, Yalgın S, Kumbasar F, Aksoy H. Haftalık 100 mg Leflunomidle Romatoid Artrit Tedavisi-Açık Çalışma. Romatizma, 2007; 22: 6-10
  9. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheumatoid arthritis: A systematic review and meta-analysis. J Rheumatol 2003; 30: 1182-90
  10. Wislowska M, Jakubicz D. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatol Int. 2007; 27: 641-7
  11. Hewitson PJ, Debroe S, McBride A, Milne R. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. J Clin Pharm Ther. 2000;25: 295-302
  12. O’Dell JR. Methotrexate, leflunomide, and combination therapies. In: Harris ED, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB (eds) Kelley’s Textbook of Rheumatology. Philadelphia, Elsever Saunders, 2005; 900-19
  13. Emery P, Cannon G, Holden W, et al. Results from a cohort of over 40,000 rheumatoid arthritis patients: Adverse event profiles of leflunomide, methotrexate and other disease-modifying antirheumatic drugs. Ann Rheum Dis 2002; 61 (Suppl. 1): 42
  14. Madison P, Kiely P, Kirkham B, Lawson T, M